NASDAQ:LTRN Lantern Pharma Q1 2026 Earnings Results & Report $0.24 -0.04 (-13.70%) Closing price 11/20/2026 03:56 PM EasternExtended Trading$0.25 +0.00 (+0.41%) As of 11/20/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lantern Pharma beat analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.30 versus the -$0.36 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 15, 2026TimeAfter Market ClosesConference Call4:00 PM ET Lantern Pharma EPS ResultsActual EPS-$0.30Consensus EPS -$0.36Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersLantern Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lantern Pharma Q1 2026 Earnings FAQ Did Lantern Pharma beat earnings estimates for Q1 2026? Lantern Pharma (NASDAQ:LTRN) reported earnings of -$0.30 per share for Q1 2026, beating the consensus estimate of -$0.36. The report was announced on Friday, May 15, 2026. Lantern Pharma Earnings HeadlinesLantern Pharma (NASDAQ: LTRN) CEO resigns and cash falls to $7.6 millionNovember 20 at 4:12 AM | americanbankingnews.comLantern Pharma (NASDAQ:LTRN) Stock Gets Downgrade from Rodman & RenshawNovember 20 at 2:18 AM | americanbankingnews.comYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on Elon Musk's next big industry play. He estimates it could create 1.8 million new millionaires in the coming years, and shows how to position in the company at its center for under $60. Inside: the company's name and ticker, plus an FCC filing James believes reveals Elon's plan to take over a $25 trillion industry. He also flags December 8 as a key date.November 21 at 1:00 AM | Paradigm Press (Ad)Lantern Pharma Reports Delay in Quarterly FilingNovember 17, 2026 | tipranks.comLantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with SpironolactoneNovember 10, 2026 | businesswire.comLantern Pharma (LTRN) Set to Announce Quarterly Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comSee More Lantern Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lantern Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lantern Pharma and other key companies, straight to your email. Email Address About Lantern PharmaLantern Pharma (NASDAQ:LTRN) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. It uses its artificial intelligence and machine-learning platform, RADR, to analyze cancer data and help identify drug candidates, potential biomarkers and patient groups that may respond to treatment. The company’s development pipeline includes investigational therapies for several cancers. Its candidates include LP-300, being studied for certain patients with non-small cell lung cancer, and LP-184 and LP-284, which are being developed for selected solid tumors and blood cancers. These therapies are investigational and are not approved medicines. Lantern Pharma is headquartered in Dallas, Texas. Panna Sharma serves as the company’s chief executive officer and is a co-founder.View Lantern Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/16 - 11/20If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in LimboAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestOwens Corning's Stock Slump May Have a Silver Lining for Dividend InvestorsThe Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity StocksHard Drives Were Left for Dead, But Seagate and Western Digital Are Soaring Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.